This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Tariffs on China will make generic drugprices go up I assume because China is such an important supplier of active pharmaceutical ingredients, as well as finished products.” 18 – The US announces it plans to improve a tariff of 25% or higher on pharmaceuticals. Pharmaceutical Commerce. Pharmaceutical Commerce.
Key Takeaways A formal trade agreement between the US and EU introduces a 15% tariff on most EU exports, including pharmaceuticals, potentially costing the pharma sector $13 billion–$19 billion. Experts recommend stockpiling medications and using forecasting tools to navigate tariff uncertainty and mitigate potential supply disruptions.
AstraZeneca will be investing $50 billion in the United States by the year 2030. billion announced in November of last year, 1 it will be investing $50 billion in the United States by the year 2030. billion announced in November of last year, 1 it will be investing $50 billion in the United States by the year 2030.
… Roche warned that President Trump’s executive order on drugpricing threatens its planned $50 billion investment in the United States , Reuters writes. The order directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations. Best of luck, everyone.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content